Oral Hypoglycaemic Agents

📋 Key Information Summary

📋

Metformin remains first-line for T2DM — reduce HbA1c by ~1.0%, weight-neutral, no hypoglycaemia risk, cardiovascular benefit in UKPDS
Sulphonylureas (gliclazide preferred) reduce HbA1c ~1.0% but carry 2–4 kg weight gain and hypoglycaemia risk; PBS-subsidised
DPP4 inhibitors (sitagliptin, linagliptin, saxagliptin) are weight-neutral, low hypoglycaemia risk, modest HbA1c reduction ~0.5–0.8%
GLP-1 receptor agonists (semaglutide, dulaglutide, liraglutide) provide 1.0–1.8% HbA1c reduction with significant weight loss; cardiovascular benefit proven
SGLT2 inhibitors (empagliflozin, dapagliflozin) reduce HbA1c ~0.5–0.8% with weight loss and demonstrated heart failure and renal protection
Choose add-on agents based on cardiovascular risk, heart failure status, CKD, weight, and hypoglycaemia risk — not HbA1c alone
SGLT2 inhibitors or GLP-1 RAs with proven CV benefit are preferred for patients with established ASCVD, HF, or CKD regardless of HbA1c
Monitor renal function (eGFR) before and during therapy with metformin, SGLT2 inhibitors, and DPP4 inhibitors; adjust doses accordingly
Metformin contraindicated if eGFR <30 mL/min; dose-reduce at eGFR 30–45; SGLT2 inhibitors initiated at eGFR ≥20 for HF/CKD benefit
HbA1c target generally <53 mmol/mol (7.0%) for most adults; individualise to <64 mmol/mol (8.0%) in elderly or comorbid patients
Combination therapy should be dual (metformin + one agent) progressing to triple if needed; consider fixed-dose combinations for adherence
Aboriginal and Torres Strait Islander peoples have higher T2DM prevalence, earlier onset, and greater complication burden — early combination and renal/CV-protective agents are essential

🎧 Audio Brief

Protecting Organs Beyond Blood Sugar

A short clinical audio briefing generated from this article — perfect for the commute or ward round.

Introduction & Australian Epidemiology

Type 2 diabetes mellitus (T2DM) affects approximately 1.3 million Australians, with prevalence continuing to rise driven by obesity, sedentary lifestyles, and ageing demographics. An estimated 280 Australians develop diabetes every day, and it remains the seventh leading cause of death nationally [1,2].

Pharmacological management of T2DM has expanded considerably beyond metformin and sulphonylureas. Contemporary oral hypoglycaemic agents and injectable therapies include dipeptidyl peptidase-4 (DPP4) inhibitors, sodium–glucose cotransporter-2 (SGLT2) inhibitors, and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), each with distinct mechanisms of action, glycaemic efficacy, and non-glycaemic benefits.

Selection of therapy must be individualised. Australian guidelines — informed by the Royal Australian College of General Practitioners (RACGP) Standards for General Practice, the Australian Diabetes Society (ADS), and the Pharmaceutical Benefits Scheme (PBS) — recommend a patient-centred approach incorporating cardiovascular risk, presence of heart failure or chronic kidney disease, body weight, hypoglycaemia risk, cost, and patient preference.

The therapeutic landscape has shifted decisively towards agents with proven cardiovascular and renal outcomes. Following landmark trials (EMPA-REG OUTCOME, LEADER, SUSTAIN-6, DAPA-HF, CREDENCE), SGLT2 inhibitors and GLP-1 RAs now occupy prominent roles not only in glycaemic management but also in cardiorenal protection — often irrespective of baseline HbA1c.

⚠️

HbA1c targets: Individualised. General target <53 mmol/mol (7.0%) for most adults; relaxed to <64 mmol/mol (8.0%) in elderly patients, those with significant comorbidities, or limited life expectancy. Avoid intensive targets in patients at high risk of hypoglycaemia-related harm.

Australian Epidemiology

Metric	Data
Total diabetes prevalence (all types)	~1.3 million diagnosed; ~500,000 undiagnosed
T2DM proportion	~85–90% of all diabetes
ATSI prevalence	~3× higher than non-Indigenous Australians
Diabetes-related hospitalisations	~240,000 per year
Diabetes as underlying cause of death	~17,000 per year (7th leading cause)
Annual health system cost	~$3.4 billion direct costs

Metformin & Sulphonylureas

Metformin

Metformin is the cornerstone first-line therapy for T2DM. It reduces hepatic glucose output, improves peripheral insulin sensitivity, and is associated with modest weight reduction or weight neutrality. The United Kingdom Prospective Diabetes Study (UKPDS) demonstrated reduced cardiovascular events in overweight patients treated with metformin [3].

💊

Metformin

Diabex® · Diaformin® · Glucophage® · Generic · Biguanide

Adult dose 500 mg PO BD with meals, titrate over 2–4 weeks to 1 g BD (max 2.5 g/day)

Modified-release 500–2000 mg PO once daily with evening meal

Paediatric dose ≥10 years: 500 mg PO OD–BD, max 2 g/day

Route Oral (standard or modified-release)

Renal adjustment eGFR 30–45: max 1 g/day; eGFR <30: contraindicated. Review at eGFR <45

Hepatic adjustment Avoid in severe hepatic impairment (risk of lactic acidosis)

Key side effects GI (nausea, diarrhoea — mitigate with slow titration or MR form); B12 deficiency with long-term use

PBS status ✔ PBS General Benefit

ℹ️

Key points: Weight-neutral or modest weight loss. No hypoglycaemia risk when used as monotherapy. Monitor B12 annually in long-term users. Temporarily withhold prior to iodinated contrast if eGFR <45 and resume 48 hours post-procedure if renal function stable.

Sulphonylureas

Sulphonylureas stimulate pancreatic beta-cell insulin secretion by closing ATP-sensitive potassium channels. They are effective second-line agents with reliable HbA1c reduction (~1.0%) but carry risks of hypoglycaemia and weight gain (2–4 kg). Gliclazide is the preferred sulphonylurea in Australia due to lower hypoglycaemia risk compared with glibenclamide (glyburide) [4].

💊

Gliclazide

Diamicron® · Glyade® · Generic · Sulphonylurea

Adult dose 40–320 mg PO daily in 1–2 divided doses (standard release); MR 30–120 mg once daily

Paediatric dose Not established; limited paediatric data

Route Oral

Renal adjustment Use with caution in renal impairment; start low. Metabolised hepatically

Hepatic adjustment Use with caution; risk of prolonged hypoglycaemia

Key side effects Hypoglycaemia, weight gain, rarely hyponatraemia (SIADH)

PBS status ✔ PBS General Benefit

💊

Glipizide

Melizide® · Generic · Sulphonylurea

Adult dose 2.5–20 mg PO daily in 1–2 divided doses, 30 min before meals

Renal adjustment Start at 2.5 mg in renal impairment

PBS status ✔ PBS General Benefit

⚠️

Hypoglycaemia warning: Sulphonylurea-induced hypoglycaemia may be prolonged and severe, particularly in elderly patients, those with renal impairment, or with missed meals. Educate patients on recognition, carry fast-acting glucose, and avoid in patients with recurrent severe hypoglycaemia.

DPP4 Inhibitors & GLP-1 Receptor Agonists

DPP4 Inhibitors (Gliptins)

DPP4 inhibitors block degradation of incretin hormones (GLP-1 and GIP), enhancing glucose-dependent insulin secretion and suppressing glucagon. They are weight-neutral with a low risk of hypoglycaemia and provide modest HbA1c reduction (~0.5–0.8%). They are well tolerated with a generally favourable safety profile [5].

💊

Sitagliptin

Januvia® · Generic · DPP4 inhibitor

Adult dose 100 mg PO once daily (with or without food)

Renal adjustment eGFR 30–50: 50 mg daily; eGFR <30: 25 mg daily

Key side effects Generally well tolerated; nasopharyngitis, URTI; rare pancreatitis; arthralgia (post-market)

PBS status PBS Restricted Benefit

💊

Linagliptin

Trajenta® · DPP4 inhibitor

Adult dose 5 mg PO once daily

Renal adjustment None required — hepatically eliminated

PBS status PBS Restricted Benefit

💊

Saxagliptin

Onglyza® · DPP4 inhibitor

Adult dose 2.5–5 mg PO once daily

Renal adjustment eGFR <45: 2.5 mg daily

PBS status PBS Restricted Benefit

GLP-1 Receptor Agonists

GLP-1 RAs mimic the incretin GLP-1, enhancing glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and promoting satiety. They offer superior HbA1c reduction (~1.0–1.8%), significant weight loss (2–6 kg), and proven cardiovascular outcomes benefit. Semaglutide (oral and subcutaneous) and dulaglutide are PBS-listed and widely used in Australian practice [6,7].

💉

Semaglutide (SC)

Ozempic® · GLP-1 RA

Adult dose 0.25 mg SC weekly ×4 wk → 0.5 mg weekly → 1.0 mg weekly (max 2.0 mg weekly)

Route Subcutaneous injection (prefilled pen)

Renal adjustment No dose adjustment; caution with dehydration risk

Key side effects GI (nausea, vomiting, diarrhoea — usually transient); risk of pancreatitis; injection-site reactions

PBS status PBS Authority Required

💉

Dulaglutide

Trulicity® · GLP-1 RA

Adult dose 0.75 mg SC weekly → 1.5 mg weekly (max 4.5 mg weekly)

Route Subcutaneous injection (single-use pen)

PBS status PBS Authority Required

💉

Liraglutide

Victoza® · GLP-1 RA

Adult dose 0.6 mg SC daily ×1 wk → 1.2 mg daily → 1.8 mg daily (max)

Route Subcutaneous injection (daily)

PBS status PBS Authority Required

⚠️

Contraindications: GLP-1 RAs are contraindicated in personal or family history of medullary thyroid carcinoma or MEN2. Discontinue if pancreatitis occurs. Not for use in T1DM. Do not combine with DPP4 inhibitors (duplicative mechanism). Reduce sulphonylurea dose when adding GLP-1 RA to mitigate hypoglycaemia risk.

SGLT2 Inhibitors

SGLT2 inhibitors block glucose reabsorption in the proximal renal tubule, promoting glycosuria and lowering blood glucose in an insulin-independent manner. Beyond glycaemic control, they offer significant cardiovascular, heart failure, and renal protective benefits demonstrated in landmark outcome trials [8,9,10].

💊

Empagliflozin

Jardiance® · SGLT2 inhibitor

Adult dose 10–25 mg PO once daily (morning, with or without food)

Renal adjustment eGFR ≥20 for HF/CKD benefit; glycaemic efficacy reduced below eGFR 45

Key side effects Genital mycotic infections, UTI, volume depletion, euglycaemic DKA, Fournier's gangrene (rare)

PBS status PBS Restricted Benefit

💊

Dapagliflozin

Forxiga® · SGLT2 inhibitor

Adult dose 10 mg PO once daily

Renal adjustment eGFR ≥20 for HF/CKD benefit; glycaemic efficacy reduced below eGFR 45

PBS status PBS Restricted Benefit

Cardiorenal Benefits

Agent	Landmark Trial	Key Outcome
Empagliflozin	EMPA-REG OUTCOME	14% reduction in 3-point MACE; 35% reduction in HF hospitalisation
Dapagliflozin	DECLARE-TIMI 58	17% reduction in HF hospitalisation; 47% reduction in renal composite (DAPA-CKD)
Empagliflozin	EMPEROR-Reduced/Preserved	HF benefit across EF spectrum, including HFpEF

🚨

Euglycaemic DKA: SGLT2 inhibitors can precipitate diabetic ketoacidosis even with normal or near-normal blood glucose levels. Suspend SGLT2 inhibitors 3–4 days prior to elective surgery. Screen for ketones (not glucose alone) if unwell. Ensure patients are counselled on sick-day rules.

Choosing Agents & Combination Therapy

Agent selection in T2DM is guided by patient-specific factors rather than a universal step-wise algorithm. The Australian Diabetes Society and RACGP recommend considering the following decision axes when choosing and combining agents.

Decision Framework

Step 1

First-Line

Metformin (unless contraindicated). Start at diagnosis alongside lifestyle modification.

Setting: All patients with T2DM at diagnosis

Step 2

Dual Therapy

Add second agent based on comorbidity profile (see algorithm below). If HbA1c >80 mmol/mol, consider starting dual therapy at diagnosis.

Setting: HbA1c above target after 3–6 months of metformin

Step 3

Triple Therapy

Add third agent or consider insulin initiation if glycaemic targets not met. Avoid DPP4i + GLP-1 RA combination.

Setting: Dual therapy failure; early insulin if symptomatic hyperglycaemia

Agent Selection by Comorbidity

Established ASCVD or high CV risk

GLP-1 RA (semaglutide, dulaglutide, liraglutide) and/or SGLT2i (empagliflozin, dapagliflozin)

Proven CV outcomes benefit — prioritise irrespective of HbA1c

Heart failure (HFrEF or HFpEF)

SGLT2i (empagliflozin or dapagliflozin) — add even if HbA1c at target

Reduces HF hospitalisation by 25–30% — proven across EF range

CKD (eGFR 20–60 or UACR >3 mg/mmol)

SGLT2i (initiate at eGFR ≥20) ± GLP-1 RA

Renal protection independent of glycaemic effect; monitor eGFR

Obesity / weight management priority

GLP-1 RA (semaglutide best weight loss) or SGLT2i

Avoid sulphonylureas and insulin if possible (weight gain)

Hypoglycaemia avoidance (elderly, drivers)

DPP4i, GLP-1 RA, SGLT2i, or metformin — avoid sulphonylureas

Low hypoglycaemia risk; relax HbA1c target to <64 mmol/mol

Cost-sensitive patients

Metformin + gliclazide (PBS-subsidised, low cost)

DPP4i and SGLT2i have PBS co-payments; GLP-1 RA higher cost

Combination Therapy — Practical Guidance

Metformin + SGLT2i: Preferred combination for patients with ASCVD, HF, CKD, or obesity. Monitor for genital infections and volume depletion.
Metformin + DPP4i: Well tolerated, weight-neutral, low hypoglycaemia risk. Suitable for elderly or those intolerant of GLP-1 RA GI effects.
Metformin + GLP-1 RA: Superior HbA1c and weight outcomes. GI side effects may limit tolerance. Reduce sulphonylurea dose if adding to existing SU therapy.
Metformin + sulphonylurea: Effective and inexpensive. Higher hypoglycaemia and weight gain risk. Consider stepping up to newer agents.
Triple therapy: Metformin + SGLT2i + GLP-1 RA is an evidence-based triple oral/injectable combination for patients with multiple comorbidities.
Fixed-dose combinations (FDC): Metformin + empagliflozin (Jardiamet®), metformin + sitagliptin (Janumet®) — improve adherence. Available on PBS.
Avoid: DPP4i + GLP-1 RA (duplicative incretin mechanism); sulphonylurea + insulin without specialist input.

✅

Practical tip: When intensifying therapy, reassess at 3–6 months. If HbA1c remains above individualised target, do not delay further escalation — therapeutic inertia contributes to complication development.

Monitoring

Ongoing monitoring ensures efficacy, safety, and early detection of complications. The following schedule is recommended for patients on oral hypoglycaemic agents.

3-monthly

HbA1c (3–6 monthly once stable); review efficacy and side effects of current agents

6-monthly

Fasting lipids, renal function (eGFR, UACR), liver function tests, B12 level (if on metformin >4 years)

Annually

Comprehensive diabetes cycle of care: BP, foot examination, eye screening (retinal photography), nephropathy assessment, medication review

At initiation

eGFR and UACR (metformin, SGLT2i, DPP4i dosing depends on renal function); hepatic function (metformin, linagliptin); educate on sick-day rules (SGLT2i)

ℹ️

HbA1c considerations: HbA1c may be unreliable in conditions affecting red cell turnover (haemolytic anaemia, haemoglobinopathies, iron deficiency, pregnancy). Consider fructosamine or continuous glucose monitoring in these settings.

Special Populations

🤰 Pregnancy

Metformin: May be continued or initiated in GDM and T2DM in pregnancy. Increasingly used off-label; discuss with obstetric team

Sulphonylureas: Glibenclamide does not cross placenta significantly — can be used in GDM. Other SUs not recommended

DPP4i, GLP-1 RA, SGLT2i: Contraindicated — insufficient safety data; discontinue prior to conception

Preferred: Insulin is first-line for pre-gestational T2DM. Metformin and glibenclamide as adjuncts in GDM

👶 Paediatrics

Metformin: Approved from age 10 years. First-line for paediatric T2DM. Dose 500 mg BD titrated to 2 g/day

DPP4i: Sitagliptin approved from age 10 in some jurisdictions; limited paediatric RCT data

GLP-1 RA: Liraglutide approved ≥10 years (SCALE trial). Semaglutide paediatric data emerging

SGLT2i: Not yet routinely approved for paediatric T2DM in Australia

👴 Elderly

Relax HbA1c target: <64 mmol/mol (8.0%) for frail elderly; prioritise avoidance of hypoglycaemia over tight glycaemic control

Avoid sulphonylureas if recurrent hypoglycaemia, falls risk, or cognitive impairment

DPP4i preferred: Weight-neutral, low hypoglycaemia risk, no dose titration; linagliptin no renal adjustment needed

SGLT2i: Caution with volume depletion and genital infections. Assess hydration and functional status

🫘 Renal Impairment

eGFR 45–60: Metformin dose-reduce (max 1–1.5 g/day); most DPP4i and SGLT2i safe

eGFR 30–45: Metformin max 1 g/day; dose-reduce sitagliptin (25 mg), saxagliptin (2.5 mg); SGLT2i continue for cardiorenal benefit

eGFR <30: Cease metformin; linagliptin 5 mg (no adjustment); GLP-1 RA caution; SGLT2i for CKD/HF benefit per trial criteria

Dialysis: Linagliptin or saxagliptin (DPP4i); GLP-1 RA with caution; avoid SGLT2i and metformin

🫁 Hepatic Impairment

Metformin: Avoid in severe hepatic impairment (Child–Pugh C) — lactic acidosis risk

Sulphonylureas: Use with caution; increased hypoglycaemia risk; hepatic metabolism

Linagliptin: Hepatically eliminated — no dose adjustment but use cautiously in severe liver disease

GLP-1 RA: Limited data in severe liver disease; semaglutide and liraglutide metabolised hepatically

🛡️ Immunocompromised

SGLT2i: Increased UTI and genital mycotic infection risk — consider avoidance in severe immunosuppression

Metformin: Safe; no immunosuppressive interaction. Monitor during acute illness (sick-day rules)

DPP4i: Generally well tolerated; no significant immunosuppressive interaction

Corticosteroid-induced hyperglycaemia: Metformin ± short-acting SU; consider insulin if persistent. DPP4i also reasonable

ATSI Health Considerations

Aboriginal and Torres Strait Islander Health

Epidemiology

T2DM prevalence in ATSI peoples is approximately 3 times that of non-Indigenous Australians. Onset is earlier (often <40 years), progression is faster, and complication rates (nephropathy, retinopathy, CVD, amputation) are significantly higher [11].

Access barriers

Remote and very remote communities face limited access to endocrinology specialists, diabetes educators, pathology services, and allied health. Transport, geographic isolation, and socioeconomic disadvantage compound these barriers.

Pharmacotherapy considerations

Early combination therapy should be strongly considered given the aggressive disease trajectory. Metformin is first-line. SGLT2i and GLP-1 RA are preferred add-ons given high CV/renal risk burden. PBS Authority processes may delay initiation — utilise Remote Area Aboriginal Health Services (RAAHS) prescribing provisions.

Culturally safe care

Engage Aboriginal Health Workers (AHWs) and Aboriginal Community Controlled Health Organisations (ACCHOs) in medication education and adherence support. Use pictorial medication charts and translated materials where English is not the primary language. Respect yarning and narrative-based health education approaches.

CKD screening

ATSI peoples have higher rates of CKD progression. Annual UACR and eGFR are mandatory. SGLT2i should be initiated early for renal protection. eGFR-based dose adjustments for metformin and DPP4i apply as per general population guidelines.

Resources

RHDAustralia clinical resources (rhdaustralia.org.au); NACCHO diabetes programmes; PBS co-payment exemptions for eligible ATSI patients through Section 100 (S100) remote area provisions.

📚 References

1. Australian Institute of Health and Welfare (AIHW). Diabetes: Australian facts. Canberra: AIHW; 2023. Cat. no. CVD 88.
2. Australian Bureau of Statistics. National Health Survey: First results. Canberra: ABS; 2022.
3. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854–865.
4. Schopman JE, Simon AC, Hoefnagel SJ, Hoekstra JB, Holleman F, Devries JH. The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas: a systematic review and meta-analysis. Diabetes Metab Res Rev. 2014;30(1):11–22.
5. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone. Diabetes Care. 2007;30(2):263–269.
6. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med. 2016;375(19):1834–1844.
7. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND). N Engl J Med. 2019;381(4):317–328.
8. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes (EMPA-REG OUTCOME). N Engl J Med. 2015;373(22):2117–2128.
9. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes (DECLARE-TIMI 58). N Engl J Med. 2019;380(4):347–357.
10. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease (DAPA-CKD). N Engl J Med. 2020;383(15):1436–1446.
11. Australian Institute of Health and Welfare (AIHW). Diabetes in Indigenous Australians. Canberra: AIHW; 2023.
12. Royal Australian College of General Practitioners (RACGP). General practice management of type 2 diabetes: 2020–2023. East Melbourne: RACGP; 2020.
13. American Diabetes Association Professional Practice Committee. Standards of Medical Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S1–S321.
14. Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022: a consensus report by the ADA and EASD. Diabetologia. 2022;65(12):1925–1966.